Does Renal Function or Heart Failure Diagnosis Affect Primary Care Prescribing for Sodium-Glucose Co-Transporter 2 Inhibitors in Type 2 Diabetes?
Open Access
- 15 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetes Therapy
- Vol. 11 (9), 2169-2175
- https://doi.org/10.1007/s13300-020-00878-y
Abstract
Introduction Sodium-glucose co-transporter 2 inhibitors (SGLT2is) are a unique class of drugs currently used in the management of type 2 diabetes (T2D). There are emerging data from cardiovascular outcome trials confirming renal and heart failure benefits of these drugs independent of glucose lowering. By contrast, the current licencing indications of these drugs are mainly limited to their glucose-lowering effects, and not to renal or heart failure benefits. It is therefore timely to ascertain whether the presence of these clinical conditions may influence prescribing choices for patients with T2D. Our aims are to report prescribing of SGLT2is in people with T2D according to their renal function and presence of heart failure. Co-prescribing with diuretics will also be explored. Methods We will perform a cross-sectional analysis of people with T2D in the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) network. The RCGP RSC includes more than 1500 volunteer practices throughout England and parts of Wales, and a representative sample of over 10 million patients. The proportion of adults with T2D ever prescribed an SGLT2i will be determined. Within this cohort, we will calculate the percentage of SGLT2is prescribed according to renal function, and the proportion of prescriptions in people with co-morbid heart failure, stratified by body mass index categories. The percentage of SGLT2is prescribed as an add-on to a diuretic or following discontinuation of prescribing for a diuretic will also be reported. Multilevel logistic regression will be performed to explore the association between heart failure and renal function, and propensity to prescribe SGLT2is. Planned Outputs The study findings will be submitted to a primary care/diabetes-focused conference, and for publication in a peer reviewed journal.Keywords
Funding Information
- AstraZeneca UK Limited
This publication has 18 references indexed in Scilit:
- Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UKBMJ Open, 2016
- Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel network: a cohort profileBMJ Open, 2016
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care, 2014
- Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical PharmacologyDiabetes Therapy, 2014
- The use of financial incentives to help improve health outcomes: is the quality and outcomes framework fit for purpose? A systematic reviewJournal of Public Health, 2013
- Miscoding, misclassification and misdiagnosis of diabetes in primary careDiabetic Medicine, 2012
- Automated identification of miscoded and misclassified cases of diabetes from computer recordsDiabetic Medicine, 2011
- Investigation and management of congestive heart failureBMJ, 2010
- A method of identifying and correcting miscoding, misclassification and misdiagnosis in diabetes: a pilot and validation study of routinely collected dataDiabetic Medicine, 2010
- The use of routinely collected computer data for research in primary care: opportunities and challengesFamily Practice, 2005